INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO
V. P. Shubin,
Yu. A. Shelygin,
S. I. Achkasov,
O. I. Sushkov,
A. A. Ponomarenko,
A. I. Arzamastseva,
A. S. Tsukanov https://doi.org/10.21294/1814-4861-2020-19-5-61-67
Abstract
Purpose: to evaluate the effect of somatic mutations of the KRAS, NRAS, BRAF genes and the status of microsatellite instability on the overall and disease-free survival of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Material and Methods. From 2012 to 2018, the study included 45 patients who underwent surgery for synchronous peritoneal carcinomatosis with colorectal cancer. In all patients, mutations of the KRAS, NRAS, BRAF genes and MSI status of the tumor and peritoneum metastases were determined using Sanger sequencing, fragment analysis and digital droplet polymerase chain reaction. The effect of mutations on patient survival was evaluated.
Results. The prevalence of somatic mutations was 69 % of patients. The discordance between the tumor and peritoneum metastases was 9 %. All tumors and peritoneum metastases were microsatellite stable. KRAS, NRAS, BRAF mutations did not affect the overall and disease-free survival (p=0.87 and p=0.85, respectively).
Conclusion. Somatic mutations in the KRAS, NRAS, or BRAF genes are not a prognostic factor affecting the overall and relapse-free survival of colorectal cancer patients with peritoneal carcinomatosis. The molecular status of primary tumor may differ from the status of peritoneal metastasis. It should be taken into account when prescribing targeted drugs.
About the Authors
V. P. Shubin
State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
PhD, Senior Researcher, Department of Laboratory Genetics,
2, Salam Adil Street, 123423-Moscow
Yu. A. Shelygin
State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
MD, Professor, Corresponding Member of RAS, Director,
2, Salam Adil Street, 123423-Moscow
S. I. Achkasov
State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
MD, Professor, Head of the Department of Colon Oncology Surgery,
2, Salam Adil Street, 123423-Moscow
O. I. Sushkov
State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
MD, PhD, Senior Researcher of colon oncology and surgery,
2, Salam Adil Street, 123423-Moscow
A. A. Ponomarenko
State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
MD, PhD, Researcher, Department of Oncology,
2, Salam Adil Street, 123423-Moscow
A. I. Arzamastseva
State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
MD, Oncologist,
2, Salam Adil Street, 123423-Moscow
A. S. Tsukanov
State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
MD, DSc, Leading Researcher, Department of Laboratory Genetics,
2, Salam Adil Street, 123423-Moscow
References
1. Losa F., Barrios P., Salazar R., Torres-Melero J., Benavides M., Massuti T., Ramos I., Aranda E. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Onco. 2014. 16(2): 128–140. doi: 10.1007/s12094-013-1053-x.
2. Shelygin Y.A., Achkasov S.I., Sushkov O.I., Ponomarenko A.A. The role of cytoreductive surgery (CRS) and intraperitoneal intraoperative chemotherapy (IIC) in the treatment of peritoneal carcinomatosis from colorectal origin. Koloproctology. 2017; 59(1): 53–58. (in Russian).
3. Koppe M.J., Boerman O.C., Oyen W.J., Bleichrodt R.P. Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies. Ann Surg. 2006; 243: 212–222. doi: 10.1097/01.sla.0000197702.46394.16.
4. Sushkov O.I., Achkasov S.I. Peritoneal colorectal carcinomatosis. Approaches to treatment (Review). Koloproctology. 2016; 58(4): 69–79. (in Russian).
5. Stepanov I.V., Paderov Yu.M., Afanasyev S.G. Peritoneal carcinomatosis. Siberian Journal of Oncology. 2014; (5): 45–53. (in Russian).
6. Ceelen W.P. Peritoneal Carcinomatosis. Springer, 2007. 548 p. doi: 10.1007/978-0-387-48993-3.
7. Tsukanov A.S., Shelygin Yu.A., Shubin V.P. Microsatellite instability in colorectal cancer (review). Koloproctology. 2017; 60(2): 100–104. (in Russian).
8. Paklina O.V., Setdikova G.R., Daabul A.S., Shubin V.P., Pospekhova N.I., Rotin D.L. The role of microsatellite instability in ampullar carcinoma. Farmateka. 2016; 321(8): 80–84. (in Russian).
9. Karapetis C.S., Khambata-Ford S., Jonker D.J., O’Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757–1765.
10. Amado R.G. Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626–1634.
11. Shubin V.P., Pospekhova N.I., Tsukanov A.S., Rybakov E.G., Panina M.V. Sushkov O.I., Achkasov S.I., Zhdankina S.N., Kashnikov V.N., Frolov S.A., Shelygin Yu.A. Frequency and spectrum KRAS mutations in different localization of colon cancer and anal cancer. Medicinskaâ genetika. 2014; 13(5): 3135. (in Russian)].
12. Ivantsov A.O., Yanus G.A., Suspitsin E.N., Anisimova E.I., Imyanitov E.N. Molecular markers of sensitivity and resistance of colorectal cancer to anti-EGFR T. Siberian Journal of Oncology. 2016; 15(1): 59–66. (in Russian). doi: 10.21294/1814-4861-2016-15-1-59-66.
13. Shubin V.P., Ponomarenko A.A., Tsukanov A.S., Maynovskaya O.A., Rybakov E.G., Panina M.V., Kashnikov V.N., Frolov S.A., Shelygin Y.A. Heterogeneity in colorectal primary tumor and synchronous liver metastases. Russian Journal of Genetics. 2018. 54(6): 698–702. doi: 10.1134/S1022795418060091.
14. Kalyan A., Kircher S., Shah H., Mulcahy M., Benson A. Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol. 2018; 9(1): 160–169. doi: 10.21037/jgo.2018.01.17.
Review
For citations:
Shubin V.P., Shelygin Yu.A., Achkasov S.I., Sushkov O.I., Ponomarenko A.A., Arzamastseva A.I., Tsukanov A.S. INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO. Siberian journal of oncology. 2020;19(5):61-67. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-5-61-67
Views:
1736
Email this article 
